The FDA has proposed excluding the active ingredients in Novo Nordisk and Eli Lilly's top obesity and diabetes drugs from the list of substances that outsourcing facilities can use for bulk compounding. This includes semaglutide (in Wegovy and Ozempic), tirzepatide (in Zepbound and Mounjaro), and liraglutide. If finalized, this would restrict mass production of cheaper compounded versions unless there is a drug shortage. The FDA argues there is no clinical need for such compounding since approved drugs are available, and it will consider public comments before making a final decision. This move aims to protect branded drug supply and pricing strategies.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
